{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesion, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","groups":[{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG000","title":"140 mcg/kg"},{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG001","title":"100 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"42 days","title":"Number of Participants With Partial Response or Complete Response (PR + CR)","type":"SECONDARY","unitOfMeasure":"Participants"}